Epi Biotech에피바이오텍
446440 · KONEX · ₩446440 · 에피바이오텍
- Market cap
- ₩51B
- Enterprise value
- —
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- —
- Net margin
- —
Financial statements not available yet. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range0.0% from the high
₩10,880Today: ₩20,000 – ₩21,950₩21,950
Returns
- 1W+9.8%
- 1M+29.1%
- 3M+75.6%
- 6M+46.3%
- YTD+46.3%
- 1Y+37.2%
- Volume today
- 37
- 0.2× the 20-day average
- Traded today
- ₩742,950
- Listed shares
- 2,306,879
- EPS (12 months)
- —
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+12.6% on Oct 27, 2026.
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Quiet- BuzzQuietBuzz 28 of 100 (50 is a normal day for this stock).
- MomentumAt a 52-week high29.2% over the last month; the price is above its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Epi Biotech stock overview
Epi Biotech (에피바이오텍, KRX: 446440) is listed on KONEX, in the Biotech & Pharma sector. Epibiotech develops drugs for hair loss, using several modalities including cell therapies, antibody drugs, gene therapies based on cells, and topical synthetic drugs. Its shares closed at ₩21,950 on Oct 27, 2026, up 12.56% on the day, giving it a market value of ₩51B.
Key facts
- Market cap
- ₩51B
- Sector
- Biotech & Pharma
- Latest price change
- +12.56%
- As of
- Oct 27, 2026
- Main business
- Epibiotech develops drugs for hair loss, using several modalities including cell therapies, antibody drugs, gene therapies based on cells, and topical synthetic drugs.
Quick answers about Epi Biotech
- What does Epi Biotech do?
- Epibiotech develops drugs for hair loss, using several modalities including cell therapies, antibody drugs, gene therapies based on cells, and topical synthetic drugs. Its lead candidate, EPI-001, is an autologous dermal papilla cell therapy for hair loss that received clinical trial approval from Korea's drug regulator in December 2023. The company also runs its own GMP manufacturing facility, offers contract manufacturing and hair-function testing services to other companies.
- What is the market cap of Epi Biotech?
- The market capitalisation of Epi Biotech was ₩51B at the close on Oct 27, 2026.
- Who are the largest shareholders of Epi Biotech?
- According to the latest official filings, the largest reported holders are Seong Jong-hyeok (27.19%, as of Mar 26, 2025); Korea Investment Partners (13.88%, as of May 12, 2025).
- When is the next earnings report from Epi Biotech?
- Korean companies rarely announce results dates in advance. Based on when Epi Biotech filed the same report in past years, its next annual results is expected between Mar 18, 2027 and Mar 23, 2027.
Company profile
Epibiotech develops drugs for hair loss, using several modalities including cell therapies, antibody drugs, gene therapies based on cells, and topical synthetic drugs. Its lead candidate, EPI-001, is an autologous dermal papilla cell therapy for hair loss that received clinical trial approval from Korea's drug regulator in December 2023. The company also runs its own GMP manufacturing facility, offers contract manufacturing and hair-function testing services to other companies.
Written by AI from the company's latest annual report.
- Korean name
- 에피바이오텍
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 성종혁
- Founded
- Dec 2015
- Listed
- Jul 2023
- Listed shares
- 2,306,879
- Fiscal year ends
- Month 12
- Website
- epibiotech.com/
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Shareholders' meeting calledOct 14, 2026
- Determination of Shareholder Register Closure Period or Record DateOct 14, 2026
- Investor relations (IR) eventOct 6, 2026
- Investor relations (IR) eventSep 17, 2026
- Annual general meeting resultsMar 31, 2026
Titles in Korean until English translations are added.
Also known as: Epi Biotech / 에피바이오텍 / 446440 / KRX:446440
Source: KRX statistical information